BeatIt-MV Therapy for Minimally Verbal Autistic Adults

N/A

Recruiting

Led By Vanessa Bal, PhD

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)

Awards & highlights

No Placebo-Only Group

Summary

"This trial is testing a new therapy called BeatIt-2 to help people with intellectual disabilities and low mood who are minimally verbal due to autism."

Who is the study for?

This trial is for minimally verbal adults over 18 with Autism Spectrum Disorder and depression, who have a support person and can travel to Rutgers University in New Jersey or New York. It's not suitable for those without these specific conditions or support.

What is being tested?

The study is testing BeatIt-MV, an adaptation of the BeatIt-2 intervention designed to help autistic individuals with intellectual disabilities and low mood by increasing their engagement in positive activities.

What are the potential side effects?

Since this is a behavioral intervention, traditional medical side effects are not applicable. However, participants may experience changes in mood or behavior due to the nature of the therapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Anxiety Depression and Mood Scale (ADAMS)

Glasgow Depression Scale for Intellectual Disability (GDS)

Mood, Interest, & Pleasure Questionnaire (MIPQ)

Secondary study objectives

Shalock Quality of Life Questionnaire

Vineland Adaptive Behavior Scale, 3rd edition (VABS-3)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: BeatIt-MV Treatment GroupExperimental Treatment1 Intervention

Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.

Do I qualify?Apply below to find out